These T cells recognized de novo trastuzumab-resistant HER2+ breast cancer cells in three-dimensional cell cultures like spheroids and showed cytotoxic effects, while trastuzumab alone failed to do so. The gene discussed is ERBB2; the disease is breast carcinoma.